Skip header and navigation

Refine By

33 records – page 1 of 4.

5-year outcome after transcatheter aortic valve implantation.

https://arctichealth.org/en/permalink/ahliterature117830
Source
J Am Coll Cardiol. 2013 Jan 29;61(4):413-9
Publication Type
Article
Date
Jan-29-2013
Author
Stefan Toggweiler
Karin H Humphries
May Lee
Ronald K Binder
Robert R Moss
Melanie Freeman
Jian Ye
Anson Cheung
David A Wood
John G Webb
Author Affiliation
St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Source
J Am Coll Cardiol. 2013 Jan 29;61(4):413-9
Date
Jan-29-2013
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Aortic Valve - physiopathology - surgery - ultrasonography
Aortic Valve Stenosis - diagnosis - epidemiology - physiopathology - surgery
Canada - epidemiology
Equipment Failure Analysis - statistics & numerical data
Female
Heart Valve Prosthesis Implantation - adverse effects - methods - mortality - statistics & numerical data
Humans
Male
Outcome and Process Assessment (Health Care)
Postoperative Period
Prognosis
Prosthesis Design
Prosthesis Failure - etiology
Risk factors
Severity of Illness Index
Survival Rate
Survivors - statistics & numerical data
Time Factors
Treatment Outcome
Abstract
The purpose of this study was to investigate the 5-year outcome following transcatheter aortic valve implantation (TAVI).
Little is known about long-term outcomes following TAVI.
The 5-year outcomes following successful TAVI with a balloon-expandable valve were evaluated in 88 patients. Patients who died within 30 days after TAVI were excluded.
Mean aortic valve gradient decreased from 46 ± 18 mm Hg to 10 ± 4.5 mm Hg after TAVI and 11.8 ± 5.7 mm Hg at 5 years (p for post-TAVI trend = 0.06). Mean aortic valve area increased from 0.62 ± 0.17 cm(2) to 1.67 ± 0.41 cm(2) after TAVI and 1.40 ± 0.25 cm(2) at 5 years (p for post-TAVI trend
PubMed ID
23265333 View in PubMed
Less detail

Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations.

https://arctichealth.org/en/permalink/ahliterature133038
Source
CMAJ. 2011 Sep 6;183(12):E817-23
Publication Type
Article
Date
Sep-6-2011
Author
Meytal A Tsadok
Cynthia A Jackevicius
Elham Rahme
Vidal Essebag
Mark J Eisenberg
Karin H Humphries
Jack V Tu
Hassan Behlouli
Jennifer Joo
Louise Pilote
Author Affiliation
Division of Internal Medicine, McGill University Health Center, Montréal, Que.
Source
CMAJ. 2011 Sep 6;183(12):E817-23
Date
Sep-6-2011
Language
English
Publication Type
Article
Keywords
Age Factors
Aged
Amiodarone - adverse effects
Anti-Arrhythmia Agents - adverse effects
Atrial Fibrillation - drug therapy
Chi-Square Distribution
Drugs, Generic - adverse effects
Female
Humans
Incidence
Income
Length of Stay - statistics & numerical data
Male
Proportional Hazards Models
Quebec - epidemiology
Retrospective Studies
Risk factors
Thyroid Diseases - chemically induced - epidemiology
Abstract
Amiodarone is associated with dysfunction of the thyroid. Concerns have arisen regarding the potential for adverse effects with generic formulations of amiodarone. We evaluated and compared the risk of thyroid dysfunction between patients using brand-name versus generic formulations of amiodarone and identified risk factors for thyroid dysfunction.
We conducted a retrospective cohort study of patients with atrial fibrillation aged 66 years and older. We used administrative databases that linked information on demographics and clinical characteristics, claims for prescription drugs and discharges from hospital. We estimated thyroid dysfunction using person-year incidence.
Of the 60,220 patients in the cohort, 2804 (4.7%) used the brand-name formulation of amiodarone and 6278 (10.4%) used the generic formulation. Baseline characteristics between these two groups were comparable. The median maintenance dose of amiodarone was 200 mg/d for both groups. The total incidence rate for thyroid dysfunction was 14.1 per 100 person-years for both formulations. The mean time to clinical dysfunction of the thyroid was 4.32 years for the brand-name formulation and 4.09 years for the generic formulation. In a multivariate analysis, there was no significant difference in the incidence rates of thyroid dysfunction between the generic and brand formulations (hazard ratio 0.97, 95% confidence interval 0.87-1.08). Factors associated with an increased risk of thyroid dysfunction were being a woman, increasing age and having chronic obstructive pulmonary disease.
In this population-based study, we saw no difference between brand-name and generic formulations of amiodarone in terms of incidence of thyroid dysfunction.
Notes
Cites: Am J Med. 2007 Oct;120(10):880-517904459
Cites: Respir Med. 2007 Jul;101(7):1439-4617346957
Cites: Wien Klin Wochenschr. 2008;120(15-16):493-818820854
Cites: JAMA. 2008 Dec 3;300(21):2514-2619050195
Cites: Braz J Med Biol Res. 2009 Aug;42(8):744-919649401
Cites: Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):735-5119942150
Cites: Nat Rev Endocrinol. 2010 Jan;6(1):34-4119935743
Cites: Swiss Med Wkly. 2010 Feb 6;140(5-6):73-719950036
Cites: Int J Pharm Pract. 2010 Aug;18(4):245-820636678
Cites: Int J Clin Pract. 2010 Jul;64(8):1069-7520487051
Cites: J Clin Endocrinol Metab. 2007 Dec;92(12):4575-8217911171
Cites: CMAJ. 2000 Feb 22;162(4):523-610701389
Cites: N Engl J Med. 2000 Mar 30;342(13):913-2010738049
Cites: Am J Cardiol. 2000 May 1;85(9):1151-3, A1010781771
Cites: Curr Opin Cardiol. 2001 Jan;16(1):23-911124715
Cites: Endocr Rev. 2001 Apr;22(2):240-5411294826
Cites: Can J Cardiol. 2001 Nov;17(11):1159-6311726984
Cites: Metabolism. 2001 Dec;50(12):1397-40111735083
Cites: J Clin Endocrinol Metab. 2002 Feb;87(2):489-9911836274
Cites: Ann Pharmacother. 2002 Nov;36(11):1682-512398559
Cites: Med Princ Pract. 2004 May-Jun;13(3):126-815073423
Cites: Am J Med. 1991 Nov;91(5):507-111951413
Cites: J Clin Epidemiol. 1995 Aug;48(8):999-10097775999
Cites: Arch Intern Med. 1995 Sep 25;155(17):1885-917677555
Cites: Endocr Rev. 1995 Dec;16(6):686-7158747831
Cites: Lancet. 1997 Mar 8;349(9053):675-829078198
Cites: J Interv Card Electrophysiol. 1999 Jul;3(2):145-710387141
Cites: Prog Cardiovasc Dis. 2004 Jul-Aug;47(1):3-1015517512
Cites: Health Policy. 2007 May;81(2-3):376-8416945449
Comment In: CMAJ. 2011 Sep 6;183(12):1350-121746827
PubMed ID
21746822 View in PubMed
Less detail

Antiarrhythmic use from 1991 to 2007: insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II).

https://arctichealth.org/en/permalink/ahliterature143905
Source
Heart Rhythm. 2010 Sep;7(9):1171-7
Publication Type
Article
Date
Sep-2010
Author
Jason G Andrade
Stuart J Connolly
Paul Dorian
Martin Green
Karin H Humphries
George J Klein
Robert Sheldon
Mario Talajic
Charles R Kerr
Author Affiliation
St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.
Source
Heart Rhythm. 2010 Sep;7(9):1171-7
Date
Sep-2010
Language
English
Publication Type
Article
Keywords
Adrenergic beta-Antagonists - therapeutic use
Anti-Arrhythmia Agents - therapeutic use
Atrial Fibrillation - drug therapy - epidemiology - physiopathology
Calcium Channel Blockers - therapeutic use
Canada - epidemiology
Electrocardiography - drug effects
Follow-Up Studies
Heart Rate - drug effects
Humans
Middle Aged
Morbidity - trends
Prospective Studies
Registries
Retrospective Studies
Time Factors
Treatment Outcome
Abstract
The pharmacologic management of atrial fibrillation (AF), the most common sustained cardiac arrhythmia, has been traditionally dichotomized into control of ventricular rate or re-establishment and maintenance of sinus rhythm.
The purpose of this study was to evaluate the use of rate-controlling drugs and antiarrhythmic drugs (AAD) in the Canadian Registry of Atrial Fibrillation (CARAF) over a 16-year period from 1991 through 2007.
1,400 patients with new-onset paroxysmal AF who were enrolled in CARAF were included in this analysis. We assessed trends in ventricular rate-controlling medication use (digoxin, beta-blockers, and calcium channel blockers) and AAD (class IA, IC, and III antiarrhythmic agents) at baseline and follow-up visits as well as by calendar year.
AAD use increased initially from 1991 to 1994 (peak use 42.5%) before steadily declining. Sotalol use decreased (27% to 6%), whereas amiodarone use increased (1.6% to 17.9%). Rate-controlling medication use decreased from 1991 to 1995 (54.1% to 34.1%) due to declining digoxin use (62.9% to 16.3%). After 1999, there was a continued increase in rate-controlling medication use (peak use 52.5% in 2007) due to increased beta-blocker use (17% to 45.7%). Calcium channel blockers use changed little over the duration of the study.
The management of AF has undergone significant shifts since 1990, reflecting the influence of drug development, prevailing belief systems, the impact of large clinical trials, and evidence-based recommendations. Monitoring of pharmacotherapy trends will provide insight into the real-world application of evidence-based guidelines as well as allow the opportunity to identify deficiencies and improve patient care.
PubMed ID
20430112 View in PubMed
Less detail

Appropriateness of current thresholds for obesity-related measures among Aboriginal people.

https://arctichealth.org/en/permalink/ahliterature159974
Source
CMAJ. 2007 Dec 4;177(12):1499-505
Publication Type
Article
Date
Dec-4-2007
Author
Scott A Lear
Karin H Humphries
Jiri J Frohlich
C Laird Birmingham
Author Affiliation
School of Kinesiology, Simon Fraser University, Burnaby, BC. slear@providencehealth.bc.ca
Source
CMAJ. 2007 Dec 4;177(12):1499-505
Date
Dec-4-2007
Language
English
Publication Type
Article
Keywords
Adult
Aged
Body mass index
British Columbia - epidemiology
Cardiovascular Diseases - diagnosis - ethnology
Comorbidity
European Continental Ancestry Group - statistics & numerical data
Female
Humans
Indians, North American - statistics & numerical data
Male
Middle Aged
Obesity - diagnosis - ethnology
Prevalence
Reference Standards
Risk Assessment - methods
Risk factors
Waist-Hip Ratio
Abstract
Despite the high prevalence of obesity and diabetes in the Canadian Aboriginal population, it is unknown whether the current thresholds for body mass index and waist circumference derived from white populations are appropriate for Aboriginal people. We compared the risk of cardiovascular disease among Canadian Aboriginal and European populations using the current thresholds for body mass index and waist circumference.
Healthy Aboriginal (n = 195) and European (n = 201) participants (matched for sex and body mass index range) were assessed for demographic characteristics, lifestyle factors, total and central adiposity and risk factors for cardiovascular disease. Among Aboriginal and European participants, we compared the relation between body mass index and each of the following 3 factors: percent body fat, central adiposity and cardiovascular disease risk factors. We also compared the relation between waist circumference and the same 3 factors.
The use of body mass index underestimated percent body fat by 1.3% among Aboriginal participants compared with European participants (p = 0.025). The use of waist circumference overestimated abdominal adipose tissue by 26.7 cm2 among Aboriginal participants compared with European participants (p = 0.007). However, there was no difference in how waist circumference estimated subcutaneous abdominal and visceral adipose tissue among the 2 groups. At the same body mass index and waist circumference, we observed no differences in the majority of cardiovascular disease risk factors among Aboriginal and European participants. The prevalence of dyslipidemia, hypertension, impaired fasting glucose and metabolic syndrome was similar among participants in the 2 groups after adjustment for body mass index, waist circumference, age and sex.
We found no difference in the relation between body mass index and risk of cardiovascular disease between men and women of Aboriginal and European descent. We also found no difference between waist circumference and cardiovascular disease risk among these groups. These data support the use of current anthropometric thresholds in the Canadian Aboriginal population.
Notes
Cites: Int J Obes Relat Metab Disord. 2000 Aug;24(8):1011-710951540
Cites: Am J Clin Nutr. 2007 Aug;86(2):353-917684205
Cites: JAMA. 2001 May 16;285(19):2486-9711368702
Cites: Lancet. 2001 Oct 6;358(9288):1147-5311597669
Cites: Metabolism. 2002 Nov;51(11):1427-3212404193
Cites: N Engl J Med. 2003 Apr 24;348(17):1625-3812711737
Cites: Metabolism. 2003 Oct;52(10):1295-30114564681
Cites: CMAJ. 2003 Oct 28;169(9):921-414581310
Cites: Am J Clin Nutr. 2004 Aug;80(2):271-815277145
Cites: Clin Chem. 1972 Jun;18(6):499-5024337382
Cites: Int J Epidemiol. 1989;18(3 Suppl 1):S46-552807707
Cites: Am J Cardiol. 1994 Mar 1;73(7):460-88141087
Cites: Med Sci Sports Exerc. 1995 Dec;27(12):1626-348614318
Cites: Hum Biol. 1996 Apr;68(2):245-638838915
Cites: Lancet. 1998 Mar 21;351(9106):853-69525361
Cites: Int J Obes Relat Metab Disord. 1998 Nov;22(11):1127-319822953
Cites: Diabetologia. 1999 Jan;42(1):28-3410027574
Cites: Am J Clin Nutr. 1999 Mar;69(3):455-6010075330
Cites: CMAJ. 2005 Apr 12;172(8):995-815824401
Cites: Int J Obes (Lond). 2005 Jun;29(6):656-6715782225
Cites: Lancet. 2005 Nov 5;366(9497):1640-916271645
Cites: Int J Obes (Lond). 2006 Apr;30(4):677-8316276358
Cites: Ethn Dis. 2006 Winter;16(1):96-10016599355
Cites: Can J Cardiol. 2006 May 15;22(7):573-8116755312
Cites: Obesity (Silver Spring). 2007 Feb;15(2):370-617299110
Cites: CMAJ. 2000 Sep 5;163(5):561-611006768
PubMed ID
18056598 View in PubMed
Less detail

The association of left atrial size and occurrence of atrial fibrillation: a prospective cohort study from the Canadian Registry of Atrial Fibrillation.

https://arctichealth.org/en/permalink/ahliterature178124
Source
Am Heart J. 2004 Oct;148(4):649-54
Publication Type
Article
Date
Oct-2004
Author
Ratika Parkash
Martin S Green
Charles R Kerr
Stuart J Connolly
George J Klein
Robert Sheldon
Mario Talajic
Paul Dorian
Karin H Humphries
Author Affiliation
University of Ottawa, Ottawa, Ontario, Canada.
Source
Am Heart J. 2004 Oct;148(4):649-54
Date
Oct-2004
Language
English
Publication Type
Article
Keywords
Aged
Atrial Fibrillation - etiology
Canada
Cardiomegaly - complications - ultrasonography
Chronic Disease
Disease Progression
Female
Heart Atria - anatomy & histology - ultrasonography
Humans
Linear Models
Male
Middle Aged
Prospective Studies
Recurrence
Registries
Risk factors
Abstract
The effect of left atrial (LA) dimension on the recurrence of atrial fibrillation (AF) has been examined in small studies. We evaluated the effect of LA dimension on the occurrence of AF using 2- and 4-year echocardiographic data in a large cohort of patients with new onset AF.
The Canadian Registry of AF (CARAF) enrolled subjects with AF at the first electrocardiographically confirmed diagnosis. Patients were classified at 2 and 4 years as no recurrent AF (No RAF), paroxysmal AF (PAF), or chronic AF (CAF) based on clinical symptoms and electrocardiographic documentation. The association between baseline, 2-, and 4-year LA dimensions with occurrence of AF as determined by echocardiography was evaluated using a multivariate analysis.
The No RAF group (n = 176) had a significantly smaller LA dimension (36.9 +/- 6.8 mm) at baseline compared to the CAF group (n = 227) (42.8 +/- 7.5 mm, P
Notes
Comment In: Am Heart J. 2006 Feb;151(2):e1; author reply e316442883
PubMed ID
15459596 View in PubMed
Less detail

Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures.

https://arctichealth.org/en/permalink/ahliterature158858
Source
CMAJ. 2008 Feb 12;178(4):405-9
Publication Type
Article
Date
Feb-12-2008
Author
Virginie Demers
Magda Melo
Cynthia Jackevicius
Jafna Cox
Dimitri Kalavrouziotis
Stéphane Rinfret
Karin H Humphries
Helen Johansen
Jack V Tu
Louise Pilote
Author Affiliation
Division of General Internal Medicine, McGill University Health Centre, Montréal, Que.
Source
CMAJ. 2008 Feb 12;178(4):405-9
Date
Feb-12-2008
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Canada
Cost Sharing - economics - trends
Drug Prescriptions - economics - statistics & numerical data
Drug Utilization - economics - trends
Health Expenditures - trends
Humans
Insurance, Pharmaceutical Services - statistics & numerical data - utilization
Middle Aged
Regional Medical Programs
Reimbursement Mechanisms
Retrospective Studies
Abstract
Reimbursement for outpatient prescription drugs is not mandated by the Canada Health Act or any other federal legislation. Provincial governments independently establish reimbursement plans. We sought to describe variations in publicly funded provincial drug plans across Canada and to examine the impact of this variation on patients' annual expenditures.
We collected information, accurate to December 2006, about publicly funded prescription drug plans from all 10 Canadian provinces. Using clinical scenarios, we calculated the impact of provincial cost-sharing strategies on individual annual drug expenditures for 3 categories of patients with different levels of income and 2 levels of annual prescription burden ($260 and $1000).
We found that eligibility criteria and cost-sharing details of the publicly funded prescription drug plans differed markedly across Canada, as did the personal financial burden due to prescription drug costs. Seniors pay 35% or less of their prescription costs in 2 provinces, but elsewhere they may pay as much as 100%. With few exceptions, nonseniors pay more than 35% of their prescription costs in every province. Most social assistance recipients pay 35% or less of their prescription costs in 5 provinces and pay no costs in the other 5. In an example of a patient with congestive heart failure, his out-of-pocket costs for a prescription burden of $1283 varied between $74 and $1332 across the provinces.
Considerable interprovincial variation in publicly funded prescription drug plans results in substantial variation in annual expenditures by Canadians with identical prescription burdens. A revised pharmaceutical strategy might reduce these major inequities.
Notes
Cites: JAMA. 2001 Jan 24-31;285(4):421-911242426
Cites: Med Care. 2001 Apr;39(4):315-2611329519
Cites: Can J Public Health. 2001 Jul-Aug;92(4):307-1211962119
Cites: CMAJ. 2002 Aug 6;167(3):246-5212186169
Cites: Int J Health Serv. 2004;34(1):101-2215088676
Cites: N Engl J Med. 1991 Oct 10;325(15):1072-71891009
Cites: Arch Intern Med. 2006 Sep 25;166(17):1829-3517000938
Cites: Health Serv Res. 1997 Apr;32(1):103-229108807
Cites: Pharmacoeconomics. 1998;14 Suppl 1:81-9610186485
Cites: Healthc Q. 2004;7(4):suppl 13-915540402
Cites: Health Policy. 2005 Feb;71(2):181-9315607380
Cites: CMAJ. 2005 Nov 22;173(11):1335-4016301701
Cites: N Engl J Med. 1994 Sep 8;331(10):650-58052275
PubMed ID
18268266 View in PubMed
Less detail

A comprehensive view of sex-specific issues related to cardiovascular disease.

https://arctichealth.org/en/permalink/ahliterature164712
Source
CMAJ. 2007 Mar 13;176(6):S1-44
Publication Type
Article
Date
Mar-13-2007
Author
Louise Pilote
Kaberi Dasgupta
Veena Guru
Karin H Humphries
Jennifer McGrath
Colleen Norris
Doreen Rabi
Johanne Tremblay
Arsham Alamian
Tracie Barnett
Jafna Cox
William Amin Ghali
Sherry Grace
Pavel Hamet
Teresa Ho
Susan Kirkland
Marie Lambert
Danielle Libersan
Jennifer O'Loughlin
Gilles Paradis
Milan Petrovich
Vicky Tagalakis
Author Affiliation
Division of Internal Medicine, The McGill University Health Centre Research Institute, McGill University, Montréal, Que. louise.pilote@mcgill.ca
Source
CMAJ. 2007 Mar 13;176(6):S1-44
Date
Mar-13-2007
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Age Factors
Aged
Atrial Fibrillation - diagnosis - epidemiology
Canada - epidemiology
Cardiovascular Diseases - diagnosis - epidemiology
Cause of Death
Child
Coronary Disease - diagnosis - epidemiology
Female
Heart Failure - diagnosis - epidemiology
Hospitalization - statistics & numerical data
Humans
Male
Middle Aged
Prevalence
Quality of Life
Risk assessment
Severity of Illness Index
Sex Distribution
Sex Factors
Survival Analysis
Abstract
Cardiovascular disease (CVD) is the leading cause of mortality in women. In fact, CVD is responsible for a third of all deaths of women worldwide and half of all deaths of women over 50 years of age in developing countries. The prevalence of CVD risk factor precursors is increasing in children. Retrospective analyses suggest that there are some clinically relevant differences between women and men in terms of prevalence, presentation, management and outcomes of the disease, but little is known about why CVD affects women and men differently. For instance, women with diabetes have a significantly higher CVD mortality rate than men with diabetes. Similarly, women with atrial fibrillation are at greater risk of stroke than men with atrial fibrillation. Historically, women have been underrepresented in clinical trials. The lack of good trial evidence concerning sex-specific outcomes has led to assumptions about CVD treatment in women, which in turn may have resulted in inadequate diagnoses and suboptimal management, greatly affecting outcomes. This knowledge gap may also explain why cardiovascular health in women is not improving as fast as that of men. Over the last decades, mortality rates in men have steadily declined, while those in women remained stable. It is also becoming increasingly evident that gender differences in cultural, behavioural, psychosocial and socioeconomic status are responsible, to various degrees, for the observed differences between women and men. However, the interaction between sex-and gender-related factors and CVD outcomes in women remains largely unknown.
Notes
Cites: N Engl J Med. 2000 Apr 20;342(16):1187-9510770985
Cites: N Engl J Med. 2000 Apr 20;342(16):1207-1010770988
Cites: J Diabetes Complications. 1999 Sep-Dec;13(5-6):277-8310765002
Cites: BMJ. 2000 Apr 22;320(7242):1102-710775217
Cites: J Intern Med. 2000 Apr;247(4):500-610792565
Cites: Circulation. 2000 May 2;101(17):2040-610790344
Cites: BMJ. 2000 May 6;320(7244):1240-310797032
Cites: Eur Heart J. 2000 Jun;21(11):911-810806015
Cites: Soc Sci Med. 2000 Jul;51(1):123-3310817475
Cites: Lancet. 2000 May 6;355(9215):1575-8110821360
Cites: Am Heart J. 2000 Jun;139(6):971-810827376
Cites: Braz J Med Biol Res. 2000 Jun;33(6):679-9110829096
Cites: N Engl J Med. 2000 Jun 15;342(24):1792-80110853003
Cites: Am J Epidemiol. 2000 May 15;151(10):1007-1910853640
Cites: N Engl J Med. 2000 Jul 6;343(1):8-1510882763
Cites: Am Heart J. 2000 Jul;140(1):126-3310874273
Cites: Diabetes Care. 2000 Jul;23(7):962-810895847
Cites: Coron Artery Dis. 2000 Jul;11(5):399-40710895406
Cites: Arch Dis Child. 2000 Jul;83(1):18-2410868993
Cites: Arch Pediatr Adolesc Med. 2003 Feb;157(2):185-9012580690
Cites: Can J Public Health. 2003 Jan-Feb;94(1):45-5112583679
Cites: Cardiology. 2003;99(1):39-4612589121
Cites: Ann Thorac Surg. 2002 Dec;74(6):2113-9; discussion 212012643404
Cites: J Am Coll Surg. 2003 Mar;196(3):428-3412648695
Cites: Nurs Res. 2003 Mar-Apr;52(2):108-1812657986
Cites: Ann Thorac Surg. 2003 Apr;75(4):1153-6012683554
Cites: Trends Cardiovasc Med. 2003 Apr;13(3):93-10112691672
Cites: J Mol Med (Berl). 2003 Apr;81(4):227-3412700890
Cites: Can J Cardiol. 2003 Mar 31;19(4):347-5612704478
Cites: Can J Cardiol. 2003 Apr;19(5):523-3112717488
Cites: Health Psychol. 2000 Jul;19(4):354-6410907654
Cites: Med Sci Sports Exerc. 2000 Jul;32(7):1250-710912890
Cites: Am J Cardiol. 2000 Jul 15;86(2):211-310913484
Cites: J Am Coll Cardiol. 2000 Aug;36(2):381-610933346
Cites: Public Health Nutr. 1998 Sep;1(3):169-7610933414
Cites: Eur Heart J. 2000 Sep;21(17):1458-6310952838
Cites: Ross Fiziol Zh Im I M Sechenova. 2000 Jun;86(6):671-8010955304
Cites: J Epidemiol. 2000 Jul;10(4):226-3310959604
Cites: Circulation. 2000 Sep 5;102(10):1082-510973834
Cites: Ann Thorac Surg. 2000 Sep;70(3):800-5; discussion 80611016313
Cites: Circulation. 2000 Oct 17;102(16):1917-2311034939
Cites: Am J Clin Nutr. 2000 Nov;72(5 Suppl):1343S-1353S11063476
Cites: Am J Med. 2000 Nov;109(7):543-811063955
Cites: J Am Coll Cardiol. 2000 Nov 1;36(5):1572-811079660
Cites: J Epidemiol Community Health. 2000 Dec;54(12):912-611076987
Cites: Circulation. 2000 Nov 14;102(20):2484-9011076821
Cites: Heart Lung. 2001 Nov-Dec;30(6):401-26; quiz 427-811723446
Cites: Am J Public Health. 2001 Dec;91(12):1995-200311726382
Cites: BMJ. 2002 Jan 12;324(7329):71-8611786451
Cites: Hypertension. 2001 May;37(5):1199-20811358929
Cites: Ital Heart J. 2001 Apr;2(4):280-611374497
Cites: Am J Epidemiol. 2001 May 15;153(10):969-7711384953
Cites: N Engl J Med. 2001 Jun 21;344(25):1879-8711419424
Cites: Md Med. 2001 Spring;Suppl:49-5911434061
Cites: J Am Coll Cardiol. 2001 Jul;38(1):41-811451294
Cites: Acta Cardiol. 2001 Jun;56(3):169-7911471930
Cites: Arch Intern Med. 2001 Jul 23;161(14):1717-2311485504
Cites: Lancet. 2001 Aug 11;358(9280):439-4411513906
Cites: J Psychosom Res. 2001 Aug;51(2):443-911516767
Cites: J Am Coll Cardiol. 2001 Sep;38(3):690-711527619
Cites: Am J Kidney Dis. 2001 Sep;38(3):529-3611532685
Cites: Pediatrics. 2001 Sep;108(3):712-811533341
Cites: Circulation. 2001 Sep 4;104(10):1108-1311535564
Cites: J Clin Endocrinol Metab. 2001 Sep;86(9):4166-7011549644
Cites: JAMA. 2001 Sep 12;286(10):1218-2711559268
Cites: Ann Thorac Surg. 2001 Sep;72(3):S1022-511565719
Cites: Arterioscler Thromb Vasc Biol. 2001 Oct;21(10):1618-2211597935
Cites: J Gend Specif Med. 2001;4(3):10-3, 2011605350
Cites: Can J Cardiol. 2004 May 1;20(6):599-60715152289
Cites: Health Qual Life Outcomes. 2004 May 5;2:2115128455
Cites: Med Care. 2004 Jul;42(7):626-3415213486
Cites: Circulation. 2004 Sep 14;110(11 Suppl 1):II1-615364829
Cites: Int J Obes Relat Metab Disord. 2004 Oct;28(10):1309-1615314624
Cites: Lancet. 2004 Sep 11-17;364(9438):937-5215364185
Cites: J Sports Sci. 2004 Aug;22(8):679-70115370482
Cites: MMWR Morb Mortal Wkly Rep. 2004 Sep 17;53(36):844-715371967
Cites: Circulation. 2004 Sep 28;110(13):1832-815381642
Cites: J Public Health (Oxf). 2004 Sep;26(3):259-6315454593
Cites: Am J Cardiol. 2004 Oct 15;94(8):997-100215476611
Cites: Semin Nephrol. 2002 Mar;22(2):127-3411891506
Cites: Am J Cardiol. 2002 Mar 15;89(6):662-611897206
Cites: Clin Exp Pharmacol Physiol. 2001 Dec;28(12):1053-511903314
Cites: Prev Med. 2002 Mar;34(3):324-3311902849
Cites: Am J Cardiol. 2002 Apr 1;89(7):825-911909567
Cites: Hypertens Res. 2002 Jan;25(1):1-311924714
Cites: Circulation. 2002 Apr 2;105(13):1526-811927513
Cites: Circulation. 2002 Apr 2;105(13):1585-9111927527
Cites: Psychol Bull. 2002 Mar;128(2):295-32911931521
Cites: Jpn Heart J. 2001 Nov;42(6):669-7611933917
Cites: Am J Epidemiol. 2002 May 1;155(9):819-2611978585
Cites: J Thromb Thrombolysis. 2002 Feb;13(1):21-611994556
Cites: Obes Res. 2002 May;10(5):379-8512006637
Cites: Int J Sports Med. 2002 May;23 Suppl 1:S39-4312012261
Cites: Ann Intern Med. 2002 May 21;136(10):723-3212020140
Cites: J Am Coll Cardiol. 2002 May 15;39(10):1608-1412020487
Cites: Lancet. 2002 Jan 19;359(9302):189-9811812552
Cites: J Hypertens. 2002 Feb;20(2):209-1711821705
Cites: Ann Thorac Surg. 2002 Feb;73(2):480-9; discussion 489-9011845863
Cites: Cardiovasc Res. 2002 Feb 15;53(3):568-7611861027
Cites: Am J Cardiol. 2002 Mar 1;89(5):511-711867033
Cites: Catheter Cardiovasc Interv. 2002 Mar;55(3):331-711870937
Cites: Hypertension. 2002 Feb;39(2 Pt 2):353-611882572
Cites: Circulation. 2002 Mar 12;105(10):1176-8111889010
Cites: Am Heart J. 1999 Nov;138(5 Pt 1):835-4210539813
Cites: CMAJ. 1999;161(8 Suppl):S3-910551206
Cites: Am J Cardiol. 1999 Nov 4;84(9A):131R-138R10568672
Cites: Am Heart J. 1999 Dec;138(6 Pt 1):1046-5710577434
Cites: Med Sci Sports Exerc. 1999 Nov;31(11 Suppl):S624-3010593538
Cites: Prev Med. 2000 Jan;30(1):70-710642462
Cites: N Engl J Med. 2000 Mar 23;342(12):836-4310733371
Cites: Can J Cardiol. 1999 Dec;15 Suppl G:1G-119G10722307
Cites: N Engl J Med. 2000 Apr 20;342(16):1163-7010770981
Cites: Lancet. 2002 Sep 7;360(9335):743-5112241831
Cites: JAMA. 2002 Oct 9;288(14):1723-712365955
Cites: JAMA. 2002 Oct 9;288(14):1728-3212365956
Cites: JAMA. 2002 Oct 23-30;288(16):2015-2212387654
Cites: Br J Educ Psychol. 2002 Sep;72(Pt 3):433-4512396315
Cites: N Engl J Med. 2002 Oct 31;347(18):1403-1112409542
Cites: Arch Pediatr Adolesc Med. 2002 Nov;156(11):1075-8012413332
Cites: Int J Obes Relat Metab Disord. 2002 Dec;26 Suppl 4:S25-812457296
Cites: Soc Sci Med. 2003 Jan;56(2):363-7412473321
Cites: N Engl J Med. 2002 Dec 12;347(24):1916-2312477941
Cites: Ann Epidemiol. 2002 Nov;12(8):535-4212495826
Cites: J Am Coll Cardiol. 2002 Dec 18;40(12):2092-10112505219
Cites: Pain. 2003 Jan;101(1-2):45-5312507699
Cites: JAMA. 2003 Jan 8;289(2):194-20212517230
Cites: Lancet. 2003 Jan 4;361(9351):13-2012517460
Cites: J Am Coll Cardiol. 2003 Jan 15;41(2):307-1412535827
Cites: J Hypertens. 2003 Jan;21(1):67-7112544437
Cites: Circulation. 2003 Jan 28;107(3):375-712551856
Cites: J Sch Health. 2002 Nov;72(9):374-8012557633
Cites: Arch Intern Med. 1995 Mar 13;155(5):469-737864703
Cites: Hypertension. 1995 Mar;25(3):305-137875754
Cites: Circulation. 1995 Mar 15;91(6):1861-717882498
Cites: Circulation. 1995 Apr 1;91(7):1952-87895352
Cites: J Am Coll Cardiol. 1995 Apr;25(5):1000-97897108
Cites: Atherosclerosis. 1994 Dec;111(2):237-467718026
Cites: JAMA. 1995 May 10;273(18):1450-67654275
Cites: Biochem Biophys Res Commun. 1995 Apr 17;209(2):554-627733925
Cites: Am J Cardiol. 1995 May 15;75(15):987-927747700
Cites: J Am Coll Cardiol. 1995 Jun;25(7):1650-57759719
Cites: Am J Cardiol. 1995 Jun 1;75(16):1107-117762494
Cites: Scand J Prim Health Care. 2003 Mar;21(1):37-4212718459
Cites: Obes Res. 2003 May;11(5):668-7312740457
Cites: JAMA. 2003 May 14;289(18):2363-912746359
Cites: J Epidemiol Community Health. 2003 Jun;57(6):444-5212775792
Cites: Sports Med. 2003;33(8):585-9812797840
Cites: Can J Cardiol. 2003 Jun;19(7):774-8112813610
Cites: Can J Cardiol. 2003 Jun;19(7):782-912813611
Cites: J Gen Intern Med. 2003 Jun;18(6):423-3112823649
Cites: Prev Med. 2003 Aug;37(2):138-4712855213
Cites: Can J Cardiol. 2003 Jul;19(8):893-90112876609
Cites: Ital Heart J. 2003 Jun;4(6):371-312898800
Cites: J Sch Health. 2003 Aug;73(6):207-1512899101
Cites: Can J Cardiol. 2003 Aug;19(9):997-100412915926
Cites: Hypertens Res. 2003 Jul;26(7):547-5212924622
Cites: Am J Cardiol. 2003 Sep 1;92(5):598-60012943885
Cites: Am J Med Genet A. 2003 Oct 15;122A(3):234-712966524
Cites: Hypertension. 2000 Nov;36(5):731-311082135
Cites: Heart. 2001 Feb;85(2):149-5211156662
Cites: Int J Obes Relat Metab Disord. 2000 Dec;24(12):1628-3511126216
Cites: J Am Coll Cardiol. 2001 Jan;37(1):175-8211153734
Cites: Am J Public Health. 2001 Jan;91(1):76-8311189829
Cites: CMAJ. 2000 Nov 28;163(11):1429-3311192647
Cites: Am J Epidemiol. 2001 Jan 15;153(2):172-8311159163
Cites: Ann Intern Med. 2001 Feb 6;134(3):173-8111177329
Cites: Circulation. 2001 Jan 23;103(3):375-8011157688
Cites: Ann Thorac Surg. 2001 Feb;71(2):507-1111235698
Cites: Atherosclerosis. 2001 Feb 15;154(3):529-3711257253
Cites: Eur Heart J. 2001 Apr;22(8):693-70111286527
Cites: Am J Public Health. 2001 Apr;91(4):618-2011291375
Cites: J Pediatr. 2001 Apr;138(4):493-811295711
Cites: Curr Cardiol Rep. 2001 May;3(3):184-9011305971
Cites: Ann Emerg Med. 2001 May;37(5):478-9411326184
Cites: Clin Cardiol. 2001 May;24(5):385-9211347626
Cites: JAMA. 2001 May 16;285(19):2486-9711368702
Cites: Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):308-1214684426
Cites: Can J Public Health. 2004 Jan-Feb;95(1):38-4414768740
Cites: Circulation. 2004 Feb 10;109(5):634-4014769686
Cites: Can J Cardiol. 2004 Jan;20(1):61-714968144
Cites: Circulation. 2004 Feb 17;109(6):e47-914970124
Cites: Int J Cardiol. 2004 Feb;93(2-3):217-2314975550
Cites: Am Heart J. 2004 Mar;147(3):457-6214999194
Cites: JAMA. 2004 Mar 10;291(10):1220-515010443
Cites: Curr Opin Lipidol. 2004 Apr;15(2):129-4315017356
Cites: Physiol Genomics. 2004 Mar 12;17(1):38-4714709677
Cites: Can J Cardiovasc Nurs. 2004;14(1):39-4515022531
Cites: J Thorac Cardiovasc Surg. 2004 Apr;127(4):1158-6515052217
Cites: Health Rep. 2001 Aug;12(4):33-4315069810
Cites: N Engl J Med. 2004 Apr 1;350(14):1387-9715070788
Cites: Eur Heart J. 2004 Apr;25(8):663-7015084371
Cites: Br J Clin Pharmacol. 2004 May;57(5):640-5115089818
Cites: Can J Cardiol. 2004 Apr;20(5):491-50015100750
Cites: JAMA. 2004 May 5;291(17):2107-1315126439
Cites: JAMA. 2004 May 12;291(18):2243-5215138247
Cites: Am J Cardiol. 1998 Oct 16;82(8A):2N-9N9809895
Cites: Am J Prev Med. 1998 Nov;15(4):298-3159838974
Cites: Thromb Haemost. 1998 Nov;80(5):749-569843166
Cites: J Women Aging. 1998;10(2):67-839870042
Cites: Hypertension. 1999 Jan;33(1 Pt 2):261-59931114
Cites: J Am Geriatr Soc. 1999 Feb;47(2):151-89988285
Cites: Circulation. 1999 Mar 23;99(11):1411-510086962
Cites: Eur Heart J. 1999 Mar;20(6):447-5510213348
Cites: Atherosclerosis. 1999 Apr;143(2):435-4310217374
Cites: Thromb Haemost. 1999 Apr;81(4):516-2110235431
Cites: Ann Thorac Surg. 1999 Apr;67(4):1097-10310320257
Cites: J Adolesc Health. 2004 Nov;35(5):360-715488429
Cites: Circulation. 2004 Oct 19;110(16):2494-715477412
Cites: J Am Diet Assoc. 2004 Nov;104(11):1684-9115499355
Cites: Eur J Epidemiol. 2004;19(9):831-915499893
Cites: Am J Med. 2004 Nov 1;117(9):657-6415501203
Cites: J Thorac Cardiovasc Surg. 1982 Sep;84(3):334-416981033
Cites: N Engl J Med. 1984 Nov 1;311(18):1144-76482932
Cites: Am Heart J. 1986 Feb;111(2):383-903946178
Cites: Lancet. 1987 Jul 4;2(8549):3-92885513
Cites: N Engl J Med. 1988 Aug 11;319(6):332-73260659
Cites: N Engl J Med. 1988 Nov 24;319(21):1379-843185648
Cites: Circulation. 1989 Jan;79(1):8-152642759
Cites: Lancet. 1989 Jan 28;1(8631):175-92563096
Cites: Pediatrics. 1989 Oct;84(4):633-412780125
Cites: JAMA. 1989 Nov 3;262(17):2395-4012795824
Cites: Arch Intern Med. 1991 Jan;151(1):97-1021985614
Cites: Rehabil Nurs. 2001 Jul-Aug;26(4):132-4012035580
Cites: Nature. 2002 Jun 20;417(6891):799-80212075331
Cites: J Am Coll Cardiol. 2002 Jun 19;39(12):1909-1612084587
Cites: J Am Coll Cardiol. 2002 Jul 17;40(2):245-5012106927
Cites: Lancet. 2002 Jul 6;360(9326):7-2212114036
Cites: Heart. 2002 Aug;88(2):119-2412117828
Cites: Heart Lung. 2002 Jul-Aug;31(4):235-4512122387
Cites: Am J Prev Med. 2002 Aug;23(2 Suppl):87-9112133742
Cites: Med Care. 2002 Jul;40(7):614-2612142777
Cites: Arch Intern Med. 2002 Aug 12-26;162(15):1689-9412153371
Cites: Arch Intern Med. 2002 Aug 12-26;162(15):1737-4512153377
Cites: Am J Cardiol. 2002 Aug 15;90(4):444-512161243
Cites: Med Sci Sports Exerc. 2002 Aug;34(8):1302-712165685
Cites: JAMA. 2002 Aug 14;288(6):701-912169073
Cites: Prev Med. 2002 Aug;35(2):107-1312200094
Cites: J Am Coll Cardiol. 2002 Aug 21;40(4):693-70212204499
Cites: Public Health. 2002 Sep;116(5):279-8412209403
Cites: Ann Intern Med. 2002 Sep 17;137(6):487-9312230349
Cites: J Behav Med. 1993 Jun;16(3):323-348350345
Cites: Arch Intern Med. 1993 Oct 11;153(19):2209-168215724
Cites: Circulation. 1993 Nov;88(5 Pt 1):2097-1038222103
Cites: Atherosclerosis. 1993 Sep;102(2):195-2078251006
Cites: Qual Assur Health Care. 1993 Sep;5(3):261-57903169
Cites: Ann Epidemiol. 1992 Jan-Mar;2(1-2):23-81342260
Cites: BMJ. 1994 Jan 8;308(6921):81-1068298418
Cites: JAMA. 1994 Mar 16;271(11):840-48114238
Cites: N Engl J Med. 1994 Apr 21;330(16):1101-68133852
Cites: Arch Intern Med. 1994 Jul 11;154(13):1449-578018000
Cites: Arterioscler Thromb. 1994 Jul;14(7):1105-138018666
Cites: Thromb Haemost. 1994 Apr;71(4):420-38052956
Cites: Lancet. 1994 Aug 27;344(8922):563-707914958
Cites: Int J Obes Relat Metab Disord. 1994 Aug;18(8):561-97951478
Cites: Lancet. 1994 Nov 19;344(8934):1383-97968073
Cites: Ann Thorac Surg. 1995 Jan;59(1):112-77818310
Cites: N Engl J Med. 1995 Mar 9;332(10):635-417845427
Cites: Atherosclerosis. 1994 Oct;110 Suppl:S83-917857390
Cites: Am J Cardiol. 1995 Feb 23;75(6):53B-57B7863975
Cites: Diabetes Care. 2005 Mar;28(3):514-2015735180
Cites: Blood Coagul Fibrinolysis. 2005 Mar;16(2):119-2415741799
Cites: Am J Prev Med. 2005 Apr;28(3):259-6615766613
Cites: J Pediatr Psychol. 2005 Apr-May;30(3):293-715784925
Cites: N Engl J Med. 2005 Mar 31;352(13):1293-30415753114
Cites: Am J Hum Genet. 2005 May;76(5):815-3215800845
Cites: JAMA. 2005 Apr 13;293(14):1759-6515827315
Cites: Obes Rev. 2005 May;6(2):113-415836460
Cites: Obes Rev. 2005 May;6(2):115-615836461
Cites: Obes Rev. 2005 May;6(2):117-2115836462
Cites: Isr Med Assoc J. 2005 Apr;7(4):228-3215847201
Cites: Can J Cardiol. 1995 Jun;11(6):477-867780868
Cites: Am J Cardiol. 1995 Aug 1;76(4):226-97618613
Cites: J Sch Health. 1995 Aug;65(6):213-97564283
Cites: Am J Hypertens. 1995 Jul;8(7):657-657546488
Cites: J Thorac Cardiovasc Surg. 1995 Nov;110(5):1344-56; discussion 1356-87475187
Cites: Am J Hypertens. 1995 Oct;8(10 Pt 1):978-868845079
Cites: J Am Coll Cardiol. 1996 Feb;27(2):277-848557894
Cites: JAMA. 1996 Mar 13;275(10):777-828598594
Cites: J Clin Epidemiol. 1996 Feb;49(2):125-348606313
Cites: Am J Cardiol. 1996 May 15;77(12):1052-68644656
Cites: J Hypertens. 1996 Mar;14(3):327-3328723986
Cites: Am J Cardiol. 1996 Aug 1;78(3):278-838759804
Cites: Am Heart J. 1996 Apr;131(4):790-58721656
Cites: N Engl J Med. 1996 Oct 3;335(14):1001-98801446
Cites: J Cardiovasc Risk. 1996 Apr;3(2):213-98836866
Cites: Can J Public Health. 1996 Jul-Aug;87(4):257-608870305
Cites: J Cardiovasc Nurs. 2001 Apr;15(3):26-3812968769
Cites: JAMA. 2003 Sep 24;290(12):1600-714506119
Cites: Am J Cardiol. 2003 Oct 1;92(7):836-914516888
Cites: J Am Diet Assoc. 2003 Oct;103(10):1326-3114520252
Cites: Arch Intern Med. 2003 Oct 13;163(18):2175-8314557215
Cites: J Thorac Cardiovasc Surg. 2003 Oct;126(4):950-814566231
Cites: Diabetes Care. 2003 Nov;26(11):3142-714578252
Cites: J Hum Hypertens. 2003 Nov;17(11):761-514578915
Cites: CMAJ. 2003 Oct 28;169(9):921-414581310
Cites: Physiol Genomics. 2003 Nov 11;15(3):243-5714532335
Cites: Circulation. 2003 Nov 25;108(21):2619-2314597589
Cites: Physiol Res. 2003;52(6):689-70014640890
Cites: Am J Cardiol. 2003 Dec 15;92(12):1419-2314675577
Cites: Prog Cardiovasc Dis. 2003 Nov-Dec;46(3):199-22914685940
Cites: J Thorac Cardiovasc Surg. 2003 Dec;126(6):2032-4314688723
Cites: Am Heart J. 2004 Jan;147(1):74-814691422
Cites: Atherosclerosis. 2004 Jan;172(1):143-914709368
Cites: Psychosom Med. 2004 Jan-Feb;66(1):42-814747636
Cites: Arch Intern Med. 1998 Feb 9;158(3):229-349472202
Cites: J Hum Hypertens. 1998 Feb;12(2):91-1109504351
Cites: JAMA. 1998 Mar 25;279(12):938-429544768
Cites: Thromb Haemost. 1998 Apr;79(4):736-409569183
Cites: JAMA. 1998 May 13;279(18):1477-829600484
Cites: N Engl J Med. 1998 Jun 4;338(23):1650-69614255
Cites: Circulation. 1998 Jun 9;97(22):2202-129631869
Cites: N Engl J Med. 1998 Jul 23;339(4):229-349673301
Cites: J Am Coll Cardiol. 1998 Jul;32(1):140-69669262
Cites: Am J Cardiol. 1998 Jul 1;82(1):76-819671013
Cites: Am J Emerg Med. 1998 Jul;16(4):363-69672451
Cites: Ann Thorac Surg. 1998 Jul;66(1):125-319692451
Cites: J Hum Hypertens. 1998 Jul;12(7):441-59702929
Cites: Am Heart J. 1998 Aug;136(2):189-959704678
Cites: JAMA. 1998 Aug 19;280(7):623-99718054
Cites: Circulation. 1998 Sep 8;98(10):946-529737513
Cites: Circulation. 1998 Sep 29;98(13):1279-859751675
Cites: Lancet. 1998 Oct 10;352(9135):1167-719777832
Cites: Arch Intern Med. 1998 Oct 12;158(18):2054-629778206
Cites: Lancet. 1999 May 8;353(9164):1547-5710334252
Cites: Pediatrics. 1999 Jun;103(6 Pt 1):1175-8210353925
Cites: Arterioscler Thromb Vasc Biol. 1999 Jun;19(6):1368-7710364066
Cites: BMJ. 1999 Jun 26;318(7200):1730-710381708
Cites: N Engl J Med. 1999 Jul 22;341(4):217-2510413733
Cites: N Engl J Med. 1999 Jul 22;341(4):226-3210413734
Cites: Am J Cardiol. 1999 Jul 8;84(1A):11J-14J10418852
Cites: N Engl J Med. 1999 Sep 2;341(10):709-1710471456
Cites: Ann Intern Med. 1999 Sep 7;131(5):363-7510475890
Cites: J Am Coll Cardiol. 1999 Sep;34(3):890-91110483976
Cites: Thromb Res. 1999 Aug 15;95(4):137-5410498384
Cites: J Pediatr. 1999 Oct;135(4):458-6410518079
Cites: J Am Coll Cardiol. 1999 Oct;34(4):1348-5910520820
Cites: N Engl J Med. 1999 Oct 28;341(18):1359-6710536129
Cites: Am J Cardiol. 2004 Nov 1;94(9):1118-2315518604
Cites: Am J Cardiol. 2004 Nov 1;94(9):1147-5215518609
Cites: Am J Cardiol. 2004 Nov 1;94(9):1161-515518611
Cites: Rom J Intern Med. 2004;42(2):371-915529627
Cites: Eur J Cardiovasc Nurs. 2004 Dec;3(4):295-30215572018
Cites: Pediatrics. 2004 Dec;114(6):1534-4415574612
Cites: JAMA. 2004 Dec 8;292(22):2727-3415585732
Cites: Patient Educ Couns. 2005 Jan;56(1):45-5415590222
Cites: Z Kardiol. 2004 Dec;93(12):954-6315599570
Cites: Am J Cardiol. 2005 Jan 1;95(1):101-415619402
Cites: J Am Coll Cardiol. 2005 Jan 4;45(1):93-715629381
Cites: Health Educ Res. 2005 Feb;20(1):1-1315253992
Cites: Health Psychol. 2005 Jan;24(1):3-1015631557
Cites: Circulation. 1991 Feb;83(2):484-911991367
Cites: Lancet. 1991 Jun 8;337(8754):1387-931674771
Cites: Circulation. 1991 Aug;84(2):527-391860198
Cites: Nature. 1991 Oct 10;353(6344):521-91656270
Cites: Ann Intern Med. 1992 May 15;116(10):785-901567092
Cites: Arch Intern Med. 1992 May;152(5):972-61580724
Cites: Arterioscler Thromb. 1992 Jul;12(7):780-81616903
Cites: Womens Health Issues. 1992 Summer;2(2):102-11; discussion 111-31617306
Cites: J Am Coll Cardiol. 1992 Aug;20(2):301-61634664
Cites: Soc Sci Med. 1992 Oct;35(7):915-231411692
Cites: Res Q Exerc Sport. 1992 Dec;63(4):341-81439157
Cites: Am J Cardiol. 1992 Dec 14;70(19):3H-9H1466315
Cites: Fam Pract Res J. 1992 Dec;12(4):383-91481708
Cites: Am J Cardiol. 1993 Feb 1;71(4):268-738427166
Cites: Prev Med. 1993 Mar;22(2):167-778483856
Cites: BMJ. 1993 May 1;306(6886):1164-68499817
Cites: JAMA. 1993 Jun 16;269(23):3002-88501842
Cites: Circulation. 1993 Jul;88(1):107-158319323
Cites: Am J Nurs. 2005 Feb;105(2):34-615674053
Cites: Ann Behav Med. 2005 Feb;29(1):2-1115677295
Cites: Int J Cardiol. 2005 Feb 28;98(3):471-715708182
Cites: Stat Med. 2005 Mar 15;24(5):791-81615532082
Cites: J Hypertens. 2005 Mar;23(3):493-715716688
Cites: Circulation. 2005 Feb 22;111(7):940-5315687113
Cites: Can J Cardiol. 2005 Feb;21(2):145-5215729413
Cites: BMC Public Health. 2005 Feb 15;5:1615713230
Cites: Rev Port Cardiol. 2005 Feb;24(2):193-20115861901
Cites: BMC Public Health. 2005 Apr 18;5:3715836794
Cites: J Am Coll Cardiol. 2005 May 3;45(9):1413-815862411
Cites: Prev Chronic Dis. 2005 Apr;2(2):A2015888231
Cites: Am J Prev Med. 2005 Jun;28(5):447-5215894148
Cites: Can J Public Health. 2005 May-Jun;96(3):212-615913088
Cites: Ann Thorac Surg. 2005 Jun;79(6):2189-9415919346
Cites: Thromb Res. 2005;116(3):223-3215935831
Cites: JAMA. 2005 Jun 15;293(23):2908-1715956636
Cites: Am J Epidemiol. 2005 Jul 1;162(1):57-6515961587
Cites: Ann Epidemiol. 2005 Jul;15(6):445-5215967392
Cites: Clin Chem. 2005 Jul;51(7):1192-20015890892
Cites: Am Heart J. 2005 Apr;149(4):645-915990747
Cites: J Am Coll Cardiol. 2005 Aug 2;46(3):497-50416053964
Cites: Eur Heart J. 2005 Aug;26(16):1633-915824077
Cites: Chest. 2005 Aug;128(2):792-716100169
Cites: MMWR Morb Mortal Wkly Rep. 2005 Sep 9;54(35):865-7016151370
Cites: J Am Coll Cardiol. 2005 Sep 20;46(6):e1-8216168273
Cites: Health Rep. 2005 Jun;16(4):23-3416190322
Cites: J Epidemiol. 2005 Sep;15(5):155-6216195635
Cites: JAMA. 2005 Oct 12;294(14):1799-80916219884
Cites: Soc Sci Med. 2005 Dec;61(11):2280-9216115712
Cites: BMJ. 2006 Jan 14;332(7533):73-816371403
Cites: JAMA. 2006 Jan 18;295(3):306-1316418466
Cites: J Intern Med. 2006 Feb;259(2):164-7216420545
Cites: Nat Genet. 2006 Feb;38(2):218-2216429159
Cites: Circulation. 2006 Feb 14;113(6):e85-15116407573
Cites: Med J Aust. 2006 Feb 20;184(4):151-416489896
Cites: J Adolesc. 2006 Jun;29(3):333-4916246411
Cites: Circulation. 2006 Dec 12;114(24):2663-7017145992
Cites: Eur Heart J. 1996 Sep;17(9):1426-318880029
Cites: Pediatrics. 1996 Oct;98(4 Pt 1):649-588885941
Cites: Acta Paediatr. 1996 Sep;85(9):1083-908888923
Cites: Am J Public Health. 1996 Nov;86(11):1577-818916523
Cites: Am J Public Health. 1997 Jan;87(1):45-509065225
Cites: Hypertension. 1997 Feb;29(2):613-89040447
Cites: Hypertension. 1997 Mar;29(3):691-99052883
Cites: J Am Coll Cardiol. 1997 Mar 1;29(3):659-649060908
Cites: Am J Cardiol. 1997 Mar 1;79(5):664-69068528
Cites: Am J Cardiol. 1997 Mar 15;79(6):722-69070548
Cites: Clin Genet. 1997 Jan;51(1):22-59084929
Cites: Eur J Cardiothorac Surg. 1997 Mar;11(3):539-469105821
Cites: Thromb Haemost. 1997 Apr;77(4):748-549134654
Cites: N Engl J Med. 1998 Jan 1;338(1):8-149414325
Cites: Circulation. 1997 Dec 16;96(12):4211-89416884
Cites: Curr Opin Cardiol. 1997 Nov;12(6):587-949429832
Cites: Arterioscler Thromb Vasc Biol. 1997 Dec;17(12):3633-89437215
Cites: Ann Intern Med. 1998 Feb 1;128(3):216-239454530
Cites: Am Heart J. 2005 Jan;149(1):121-815660043
Cites: Can J Diet Pract Res. 2004 Summer;65(2):81-415217526
Cites: Am J Hypertens. 2004 Jul;17(7):624-815233982
Cites: Am J Hypertens. 2004 Jul;17(7):629-3515233983
Cites: Ann N Y Acad Sci. 2004 Jun;1019:106-1015247001
Cites: Ann N Y Acad Sci. 2004 Jun;1021:175-9715251888
Cites: Acta Cardiol. 2004 Jun;59(3):275-8115255459
Cites: Can J Cardiol. 2004 Jul;20(9):869-7615266356
Cites: JAMA. 2004 Jul 21;292(3):344-5015265849
Cites: Am J Prev Med. 2004 Aug;27(2 Suppl):25-3315275671
Cites: Am J Med. 2004 Aug 15;117(4):228-3315308431
Cites: Am J Cardiol. 2004 Aug 15;94(4):500-415325940
Cites: J Cardiovasc Nurs. 2004 Jul-Aug;19(4):251-6815326981
Cites: J Womens Health (Larchmt). 2004 Jul-Aug;13(6):695-70215333284
Cites: Eur Heart J. 2004 Sep;25(18):1641-5015351164
Cites: J Am Coll Cardiol. 2004 Aug 4;44(3):671-71915358045
Cites: Circulation. 2005 Jan 25;111(3):271-715655132
Cites: J Lab Clin Med. 2005 Jan;145(1):41-615668660
Erratum In: CMAJ. 2007 Apr 24;176(9):1310
PubMed ID
17353516 View in PubMed
Less detail

Cost comparison of ablation versus antiarrhythmic drugs as first-line therapy for atrial fibrillation: an economic evaluation of the RAAFT pilot study.

https://arctichealth.org/en/permalink/ahliterature155107
Source
J Cardiovasc Electrophysiol. 2009 Jan;20(1):7-12
Publication Type
Article
Date
Jan-2009
Author
Yaariv Khaykin
Xiaoyin Wang
Andrea Natale
Oussama M Wazni
Allan C Skanes
Karin H Humphries
Charles R Kerr
Atul Verma
Carlos A Morillo
Author Affiliation
Division of Cardiology, Southlake Regional Health Center, Newmarket, Ontario, Canada. y.khaykin@utoronto.ca
Source
J Cardiovasc Electrophysiol. 2009 Jan;20(1):7-12
Date
Jan-2009
Language
English
Publication Type
Article
Keywords
Anti-Arrhythmia Agents - economics - therapeutic use
Atrial Fibrillation - economics - epidemiology - therapy
Canada - epidemiology
Catheter Ablation - economics - utilization
Computer simulation
Cost-Benefit Analysis
Female
Health Care Costs - statistics & numerical data
Humans
Male
Models, Economic
Treatment Outcome
Abstract
Radiofrequency ablation (RFA) has become an accepted therapy for atrial fibrillation (AF). The objective of this study was to perform an economic evaluation of RFA versus antiarrhythmic drug therapy (AAD) as first-line treatment of symptomatic paroxysmal AF.
To estimate and compare the costs of RFA versus AAD, a decision analytic model was developed using data on AF recurrence, hospitalization rates, AAD use, and treatment crossover rates derived directly from the Randomized Trial of RFA versus AAD as First-Line Treatment of Symptomatic Atrial Fibrillation (RAAFT). Resource utilization was modeled to reflect Canadian clinical practice in AF management. Unit costs of healthcare interactions were based on available Canadian government resources and published literature. Costs were assessed based on intention-to-treat. Total expected costs were computed to include initial treatment, hospital stay, physician fees, diagnostic tests, and outpatient visits. Sensitivity analyses were performed to account for the uncertainties. The study was conducted from the third party payer's perspective and costs are reported in 2005 Canadian dollars with 3% discount rate used in the analysis.
During the 2-month blanking period following therapy selection, total average costs for RFA and AAD were $10,465 and $2,556, respectively; at 1-year follow-up, these were $12,823 and $6,053; and total 2-year cumulative total average costs were $15,303 and $14,392. Sensitivity analyses did not alter the results, suggesting the model is robust.
RFA as first-line treatment strategy in patients with symptomatic paroxysmal AF was cost neutral 2 years after the initial procedure compared to AAD.
PubMed ID
18803564 View in PubMed
Less detail

Cross-provincial use of cardiac services: the importance of data-sharing for clinical registries and outcomes research.

https://arctichealth.org/en/permalink/ahliterature175673
Source
Can J Cardiol. 2005 Mar;21(3):267-72
Publication Type
Article
Date
Mar-2005
Author
Karin H Humphries
Ronald G Carere
Mona Izadnegahdar
P Diane Galbraith
Merril L Knudtson
William A Ghali
Author Affiliation
St Paul's Hospital, Vancouver, Canada. khumphries@providencehealth.bc.ca
Source
Can J Cardiol. 2005 Mar;21(3):267-72
Date
Mar-2005
Language
English
Publication Type
Article
Keywords
Adult
Age Distribution
Aged
Alberta
Angioplasty, Balloon, Coronary - utilization
Bias (epidemiology)
British Columbia
Cardiac Catheterization - utilization
Community Health Planning
Cooperative Behavior
Coronary Artery Bypass - utilization
Data Collection - methods
Data Interpretation, Statistical
Databases, Factual - utilization
Female
Health Care Surveys
Health Services Accessibility - statistics & numerical data
Hospitalization - statistics & numerical data
Humans
Insurance Claim Reporting
Male
Medical Record Linkage - methods
Middle Aged
Outcome Assessment (Health Care) - methods
Registries
Sex Distribution
Abstract
The structure of the Canadian health care system lends itself to health services and health outcomes research. It is possible to track hospital admissions and discharges, physician billings and prescriptions using administrative databases. In addition, several provinces have developed registries that provide detailed clinical and procedural information. Using the unique personal health numbers assigned to all Canadian residents, linkage between administrative databases and population-based clinical registries provides important information regarding the use of health services and health outcomes.
To determine the extent of cross-border (British Columbia-Alberta border) use of cardiac services by British Columbia residents.
Population rates of cardiac procedures were calculated using two prospective clinical registries (British Columbia Cardiac Registries and Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease [APPROACH]), as well as administrative databases (the British Columbia Ministry of Health's hospitalization and Medical Services Plan databases).
Analyses using only British Columbia data suggest low cardiac procedure rates for patients living in eastern British Columbia. By accessing APPROACH data, it was determined that more than 80% of British Columbia cardiac patients living along the British Columbia-Alberta border access procedural services in Alberta.
While residents of eastern British Columbia appear to have reduced access to cardiac services when data from British Columbia are analyzed in isolation, they are actually accessing care in Alberta. Analyses based solely on single province data sources will underestimate cardiac procedures rates.
PubMed ID
15776116 View in PubMed
Less detail

Do younger women fare worse? Sex differences in acute myocardial infarction hospitalization and early mortality rates over ten years.

https://arctichealth.org/en/permalink/ahliterature106265
Source
J Womens Health (Larchmt). 2014 Jan;23(1):10-7
Publication Type
Article
Date
Jan-2014
Author
Mona Izadnegahdar
Joel Singer
May K Lee
Min Gao
Christopher R Thompson
Jacek Kopec
Karin H Humphries
Author Affiliation
1 School of Population and Public Health, University of British Columbia , Vancouver, British Columbia, Canada .
Source
J Womens Health (Larchmt). 2014 Jan;23(1):10-7
Date
Jan-2014
Language
English
Publication Type
Article
Keywords
Acute Disease
Adult
Age Factors
Aged
Aged, 80 and over
British Columbia - epidemiology
Comorbidity
Female
Hospital Mortality - trends
Hospitalization - statistics & numerical data - trends
Humans
Incidence
Logistic Models
Male
Middle Aged
Myocardial Infarction - mortality
Population Surveillance
Prevalence
Retrospective Studies
Risk factors
Severity of Illness Index
Sex Distribution
Sex Factors
Survival Rate
Abstract
Recent research has identified younger women as an "at-risk" population with rising prevalence of cardiac risk factors and excess mortality risk following acute myocardial infarction (AMI). However, population-based data on trends in AMI hospitalization and early mortality post AMI among younger adults is scarce. We, therefore, aimed to provide a 10-year, descriptive analysis of these trends in a Canadian setting.
We assessed trends and sex differences in AMI hospitalization and 30-day mortality rates using negative binomial and logistic regression, respectively. From 2000 to 2009, there were 70,628 AMI hospitalizations in adults aged =20 years, in British Columbia, Canada, with 17.1% of cohort being younger adults =55 years. Overall, age-standardized AMI rates (per 100,000 population) declined similarly in men (295.8 to 247.7) and women (152.1 to 128.8) [sex-year interaction p=0.81]. However, these trends differed according to age (age-sex-year interaction p=0.02) with increased rates observed only in younger women (+1.7% per year; p=0.04). The 30-day mortality rates declined similarly for women (19.4% to 13.9%) and men (13.0% to 9.3%) (sex-year interaction p=0.33). Yet, younger women continued to have excess mortality risk, compared with younger men, even in the most recent period [odds ratio: (2008-09)=1.61 (95% onfidence interval: 1.25, 2.08)].
While the overall AMI hospitalization and 30-day mortality rates significantly declined in women and men, hospitalization rates in women =55 years increased and their excess risk of 30-day mortality persisted. These findings highlight the need to intensify strategies to reduce the incidence of AMI and improve outcomes after AMI in younger women.
PubMed ID
24206026 View in PubMed
Less detail

33 records – page 1 of 4.